Latest Reperfusion injury Stories

2008-09-02 06:00:06

Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, today announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany. The Phase II clinical trial of FX06 (F.I.R.E. study) in 234 patients with acute myocardial infarcts was completed in March...

2008-07-02 09:00:13

RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that it received a second $100,000 award from the State of Maryland Industrial Partnerships (MIPS) program after successful completion of the first year's research goals. The Company is working with the University of Maryland, Baltimore (UMB) to develop a novel pharmaceutical product specifically aimed at preventing reperfusion injury associated with cardiac ischemia (heart attack). RegeneRx is contributing...

2005-08-12 14:39:03

NEW YORK (Reuters Health) - After resuscitation from cardiac arrest, there's a high risk of the patient dying from intractable shock, but this may be averted in some cases by a blood filtering procedure, according to a small study. Lack of circulation followed by restoration of blood flow -- ischemia-reperfusion -- is known to cause widespread damage to blood vessels. This is thought to lead to death by multiple organ failure following successful resuscitation, Dr. Mehran Monchi and...

2005-07-14 10:22:34

NEW YORK (Reuters Health) - Early restoration of blood flow to the heart after a heart attack saves lives in the short term and a new study shows that the early survival benefits associated with so-called reperfusion therapy last for at least 20 years and probably for the rest of a person's lifetime. "All efforts should be made to identify patients with evolving (heart attack), and to provide rapid, effective reperfusion therapy without delay," study investigators write in the Journal of...

2004-11-28 03:00:13

Post-acute myocardial infarction (AMI) syndrome was first described by Dressler in 1956. Its incidence has decreased in the reperfusion era, most likely because of the extensive use of thrombolysis and coronary balloon angioplasty, therapies that dramatically decreased the size of myocardial necrosis. The authors suggest that drugs that have been prescribed in previous decades as the post-AMI "standard-of-care," such as angiotensin-converting enzyme inhibitors, β-blockers, and statins,...

Word of the Day
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'